Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Ann Intern Med. 2019 Aug 20;171(5):318–327. doi: 10.7326/M18-2753

Figure 1.

Figure 1.

Cumulative incidence of HCC in the pooled propensity score–matched cohort (n = 16 668), by lipophilic statin use, hydrophilic statin use, or nonuse.

Statin use was defined as ≥30 cDDDs of filled statin prescriptions; nonuse was defined as <30 cDDDs or never-use. P < 0.001 for lipophilic statin users versus nonusers; P = 0.38 for hydrophilic statin users versus nonusers. P values were calculated using the Gray test for equality of the cumulative incidence functions between each group, with accounting for competing risks for death, emigration, and liver transplant. cDDD = cumulative defined daily dose; HCC = hepatocellular carcinoma.

* Atorvastatin and/or simvastatin.

† Rosuvastatin and/or pravastatin.